S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH

Similar documents
S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH

Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT. Moderation: S. Rauh, Esch, LU

Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES

Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception

ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain

:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B

Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018

CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves Douillard, France

PRECEPTORSHIP PROGRAMME

Colorectal Cancer Multidisciplinary management, standards of care and future perspectives

Amphithéâtre Bordeaux. Amphithéâtre. C. Massard, Villejuif, CEDEX/FR. N. Rizvi, New York, NY/US

ESMO Symposium on Immuno-Oncology Programme book

CLINICAL ONCOLOGY March 2012 Ermatingen (Lake Constance), Switzerland

ICLIO National Conference

CLINICAL ONCOLOGY 3 RD BALKAN AND EASTERN EUROPEAN MASTERCLASS IN May 2013 Dubrovnik, Croatia. Chair: R. Popescu, CH/RO Co-chair: S.

Gastric Cancer Co-Chairs Speakers LEARNING OBJECTIVES

ONCOLOGY NURSING 9 TH ESO-EONS MASTERCLASS IN March 2016 Ermatingen (Lake Constance) Switzerland #16MON

10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING march 2017 nauen ot Groß Behnitz (Berlin area), Germany. masterclass

ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY November 2018 Yerevan, Armenia MASTERCLASS

New Developments in Cancer Treatment. Ian Rabinowitz MD

High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT)

W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES

ROOM: CONRAD + ARNOLD. ROOM: CONRAD + ARNOLD Focus on ESO, ESMO and EONS Nicholas Pavlidis, Rolf Stahel,

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Programme - Friday, 7 September

MEDICAL ONCOLOGY ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN. 27 June - 2 July 2014 Brdo, Slovenia. Chairs: T. Cufer, SI R.

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

ESOU programme Prostate cancer screening: Why screening programme should not be adopted in > 65 A. Heidenreich, Aachen (DE)

Outcomes Report: Accountability Measures and Quality Improvements

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.

Cancer Prevention & Control in Adolescent & Young Adult Survivors

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE

October 6-7, 2017 Marseille, France

4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2018 Mexico City, Mexico LATIN-AMERICA PROGRAMME

SUPPLEMENTARY INFORMATION

Keytruda. Keytruda (pembrolizumab) Description

CANCER BIOLOGY FOR CLINICIANS

Progress in Tumor Research

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017

oncology For 9 th eso-esmo course on July 2012 ioannina, Greece

Keytruda. Keytruda (pembrolizumab) Description

Room A. Title: Introduction to immunotherapy in cancer Chair(s): K. Kerr, GB; P. Romero, CH. Room A. Title: Opening and welcome.

Programme - Wednesday, 5 September

ONCOLOGY NURSING 6 TH ESO-EONS MASTERCLASS IN March 2013 Ermatingen (Lake Constance) Switzerland MASTERCLASS

ASKLEPIOS Course SYMPOSIUM ON IMAGING HALLMARKS OF CANCER. Education in partnership. October 18 19, 2018 Lisbon/Portugal. myesr.

Keytruda. Keytruda (pembrolizumab) Description

First SAMO Workshop on Multidisciplinary Approaches to Gastrointestinal Tumors

Merck Oncology Overview ASCO 2017

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

Studienverzeichnis Medizinische Onkologie

Merck Oncology Overview ASCO 2017

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Outcomes Report: Accountability Measures and Quality Improvements

Gastrointestinal Oncology

Saturday, 13 February 2016

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress

6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R.

Pembrolizumab in combination with epacadostat for unresectable or metastatic melanoma

3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany

Chair: W. Eberhardt, DE; S. Peters, CH. 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A. 13:30-13:45 Opening and Welcome Room B

Macmillan Publications

ONCOLOGY NURSING March 2012 Ermatingen (Lake Constance), Switzerland

See Important Reminder at the end of this policy for important regulatory and legal information.

TUESDAY, 18th OCTOBER, 2016 / DAY -2

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

JY Douillard MD, PhD Professor of Medical Oncology

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016

TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)

Immunotherapy Treatment Developments in Medical Oncology

SCOTTISH ONCOLOGY SUMMIT Double Tree by Hilton, Dunblane Hydro, Dunblane 1 st - 2 nd September 2017

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients

Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.

Cancer diagnosis and treatments- brief overview of the changing paradigm.

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Keytruda (pembrolizumab)

Dr. Andres Wiernik. Lung Cancer

I. Diagnosis of the cancer type in CUP

Infographic (right): ESMO 2014 record breaking Congress

Wojciech Nowak, Rector of the Jagiellonian University Medical College, Kraków (PL)

State of the Art Symposium

K-Ras signalling in NSCLC

Program Schedule. Discussion 2: Is There a Role for Non-Operative Management? Case Presenter: Chris L. Hallemeier, M.D.

LUNG CANCER. ASCO Poster Review. Paolo Bironzo Department of Oncology University of Torino S. Luigi Gonzaga Hospital Orbassano (TO)

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA

Transcription:

27.04.2018 10:30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome to the Symposium S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH 10:45-12:15 Standards in NSCLC in 2018 Sala B Moderation: M. Garassino, S. Rauh ; Milan, IT, Esch Sur Alzette, LU 10:45-11:05 Standards of care in locally advanced, unresectable NSCLC M. Garassino, Milan, IT 11:05-11:10 Case presentation and discussion: Locally advanced unresectable NSCLC - immuno following radio-chemo 11:10-11:25 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 11:25-11:30 Case presentation and discussion: Adjuvant treatment oncogene-addicted NSCLC anti EGFR / same for ALK, Ros, etc. 11:30-11:45 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 11:45-11:50 Case presentation and discussion: Metastatic oncogene addicted, PD-L1 post: treatment schedule? 11:50-12:05 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 12:05-12:15 Conclusion and future outlook M. Garassino, Milan, IT 12:15-13:15 Lunch Sala B

13:15-13:45 Keynote lecture Sala B Moderation: 13:15-13:45 Immunotherapy in 2018: Hope, hype or breakthrough: An overview of use and benefit in current knowledge 13:45-15:15 Standards in melanoma in 2018 Sala B Moderation: R. Curca, O. Michielin ; Alba Iulia, RO, Lausanne, CH 13:45-13:50 Introduction and overview of the most relevant, practice-changing abstracts in 2017 R. Curca, Alba Iulia, RO 13:50-14:10 Standards of care in metastatic melanoma O. Michielin, Lausanne, CH 14:10-14:20 Case presentation: BRAF WT patient R. Curca, Alba Iulia, RO 14:20-14:40 Discussion R. Curca 1, O. Michielin 2 ; 1 Alba Iulia, RO, 2 Lausanne, CH 14:40-14:50 Case presentation: BRAF mutant patient R. Curca, Alba Iulia, RO 14:50-15:10 Discussion R. Curca 1, O. Michielin 2 ; 1 Alba Iulia, RO, 2 Lausanne, CH 15:10-15:15 Conclusions and future outlook O. Michielin, Lausanne, CH 15:15-15:45 Coffee break Sala B

15:45-17:30 Standards in colorectal cancer in 2018 Sala B Moderation: M. Karamouzis, D. Arnold ; Kolonaki, Athens/GR, Hamburg, DE 15:45-15:55 Introduction M. Karamouzis 1, D. Arnold 2 ; 1 Kolonaki, GR, 2 Lisbon, PT 15:55-16:20 Are we ready to change the duration of adjuvant chemotherapy in 2018? Adjuvant treatment of rectal cancer what s new in 2018? D. Arnold, Hamburg, DE 16:20-16:45 Metastatic colorectal cancer - what s new in 2018? M. Karamouzis, Kolonaki, GR 16:45-16:50 Case presentation: Early stage disease M. Karamouzis, Kolonaki, GR 16:50-17:05 Discussion D. Arnold, Hamburg, DE 17:05-17:10 Case presentation: Metastatic stage disease D. Arnold, Lisbon, PT 17:10-17:25 Discussion M. Karamouzis, Kolonaki, Athens/GR 17:25-17:30 Conclusions and future outlook D. Arnold 1, M. Karamouzis 2 ; 1 Hamburg, DE, 2 Kolonaki, Athens/GR

17:30-19:00 Standards in non-hodgkin's lymphoma in 2018 Sala B Moderation: R. Eckert, M. Ghielmini ; Esslingen, DE, Bellinzona, CH 17:30-17:35 Introduction 17:35-17:55 Standards of care in NHL M. Ghielmini, Bellinzona, CH 17:55-18:05 Case presentation 1 18:05-18:25 Discussion R. Eckert 1, M. Ghielmini 2 ; 1 Esslingen, DE, 2 Bellinzona, CH 18:25-18:35 Case presentation 2 18:35-18:55 Discussion R. Eckert 1, M. Ghielmini 2 ; 1 Esslingen, DE, 2 Bellinzona, CH 18:55-19:00 Conclusions and future outlook M. Ghielmini, Bellinzona, CH 28.04.2018

09:00-10:30 Standards in locally advanced, non-metastatic upper GI cancers (Gastroesophageal) in 2018 Sala B Moderation: G. Lakatos, M. Ducreux ; Budapest, HU, Villejuif, CEDEX/FR 09:00-09:05 Introduction G. Lakatos, Budapest, HU 09:05-09:25 Standards of care in upper GI cancers M. Ducreux, Villejuif, CEDEX/FR 09:25-09:35 Case presentation: Locally advanced oesophageal cancer G. Lakatos, Budapest, HU 09:35-09:55 Discussion G. Lakatos 1, M. Ducreux 2 ; 1 Budapest, HU, 2 Villejuif, CEDEX/FR 09:55-10:05 Case presentation: Locally advanced gastric cancer G. Lakatos, Budapest, HU 10:05-10:25 Discussion G. Lakatos 1, M. Ducreux 2 ; 1 Budapest, HU, 2 Villejuif, CEDEX/FR 10:25-10:30 Conclusions and future outlook M. Ducreux, Villejuif, CEDEX/FR 10:30-11:00 Coffee break Sala B

11:00-12:30 Standards in metastatic prostate cancer in 2018 Sala B Moderation: A. Froebe, M. De Santis ; Zagreb, HR, Berlin, DE 11:00-11:05 Introduction A. Froebe, Zagreb, HR 11:05-11:25 Standards of care in metastatic prostate cancer M. De Santis, Coventry, GB 11:25-11:35 Case presentation: Metastatic prostate cancer upon initial diagnosis: CHAARTED, etc. A. Froebe, Zagreb, HR 11:35-11:55 Discussion A. Froebe 1, M. De Santis 2 ; 1 Zagreb, HR, 2 Coventry, GB 11:55-12:05 Case presentation: CRPC incl. therapeutic use of isotopes in metastatic prostate cancer A. Froebe, Zagreb, HR 12:05-12:25 Discussion A. Froebe 1, M. De Santis 2 ; 1 Zagreb, HR, 2 Coventry, GB 12:25-12:30 Conclusions and future outlook M. De Santis, Berlin, DE 12:30-13:30 Lunch Sala B 13:30-14:00 Keynote lecture: San Salvatore award lecture Sala B Moderation: R.A. Stahel, S. Rauh ; Zürich, CH, Esch Sur Alzette, LU 13:30-14:00 To be announced

14:00-15:30 Standards in bladder and kidney metastatic cancers in 2018 Sala B Moderation: J. Molitor, Y. Vano; Paris, FR 14:00-14:05 Introduction J. Molitor, Paris, FR 14:05-14:25 Standards of care in bladder and kidney cancer Y. Vano, Paris, FR 14:25-14:35 Case presentation: Immunotherapy in kidney cancer: When? J. Molitor, Paris, FR 14:35-14:55 Discussion J. Molitor, Y. Vano; Paris, FR 14:55-15:05 Case presentation: Second-line treatment for bladder cancer J. Molitor, Paris, FR 15:05-15:25 Discussion Y. Vano, J. Molitor; Paris, FR 15:25-15:30 Conclusions and future outlook Y. Vano, Paris, FR 15:30-16:00 Coffee break Sala B

16:00-17:30 Standards in breast cancer in 2018 Sala B Moderation: S. Braga, A. Gennari ; Lisbon, PT, Genova, IT 16:00-16:20 Standards of care in neo-adjuvant /adjuvant breast cancer A. Gennari, Genova, IT 16:20-16:30 Case presentations: An (elderly) patient with HER2 neo adjuvant - adjuvant treatment S. Braga, Lisbon, PT 16:30-16:45 Discussion S. Braga 1, A. Gennari 2 ; 1 Lisbon, PT, 2 Genova, IT 16:45-17:05 Standards of care in metastatic breast cancer, including CDK4 inhibitors and impact on treatment A. Gennari, Genova, IT 17:05-17:15 Case presentation: Who benefits from CDK4 inhibitors? Toxicity issues S. Braga, Lisbon, PT 17:15-17:30 Discussion and future outlook S. Braga 1, A. Gennari 2 ; 1 Lisbon, PT, 2 Genova, IT 17:30-18:00 Workshop: Managing survivorship care Sala B Moderation: 17:30-17:50 ESMO guidelines and survivorship guide 17:50-18:00 Interactive discussion 18:00-19:00 Networking Foyer 29.04.2018

09:00-10:30 Standards in multiple myeloma in 2018 Sala B Moderation: R. Eckert, J. Harousseau ; Esslingen, DE, Nantes, CEDEX 1/FR 09:00-09:05 Introduction (including overview of the 4 most relevant, practice-changing abstracts in 2017) 09:05-09:35 Standards of care in multiple myeloma J. Harousseau, Nantes, CEDEX 1/FR 09:35-09:45 Case presentation 1 09:45-10:00 Discussion R. Eckert 1, J. Harousseau 2 ; 1 Esslingen, DE, 2 Nantes, FR 10:00-10:10 Case presentation 2 10:10-10:25 Discussion R. Eckert 1, J. Harousseau 2 ; 1 Esslingen, DE, 2 Nantes, FR 10:25-10:30 Conclusions and future outlook J. Harousseau, Nantes, FR 10:30-11:00 Coffee break Sala B

11:00-12:00 Workshop: Management of immunotherapy related toxicity Sala B Moderation: S. Rauh, J. Haanen ; Esch Sur Alzette, LU, Amsterdam, NL 11:00-11:03 Case: Skin toxicity 11:03-11:12 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:12-11:15 Management proposal 11:15-11:18 Case: Hepatotoxicity 11:18-11:27 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:27-11:30 Management proposal 11:30-11:33 Case: Lung toxicity 11:33-11:42 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:42-11:45 Management proposal 11:45-11:48 Case: Endocrine or other 11:48-11:57 Discussion 11:57-12:00 Management proposal

12:00-12:30 Workshop: Allergic reactions to chemotherapy- Management including desensibilisation Sala B Moderation: H. van Halteren, Vlissingen, NL 12:00-12:20 The allergologist s contribution to chemo allergies H. van Halteren, Vlissingen, NL 12:20-12:30 Discussion 12:30-12:45 Closing remarks Sala B Moderation: 12:30-12:45 Closing remarks S. Rauh, Esch, LU 12:45-13:15 Lunch Foyer